Correlation of metallothionein expression with clinical progression of cancer in the oral cavity

Anticancer Research

Volumn 29, Issue 2, 2009, Pages 589-595

  Szelachowska, Jolanta ^a   Dziegiel, Piotr ^a,c   Jelen Krzeszewska, Joanna ^a   Jelen, Michal ^a   Tarkowski, Radoslaw ^a   Spytkowska, Barbara ^b   Matkowski, Rafal ^a   Kornafel, Jan ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b Dolnoslaskie Centrum Onkologii Wroclaw   (Poland)

^c POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Laminin; Lymph nodes m tastases; Metallothionein; Oral cancer; Proliferation

Indexed keywords

KI 67 ANTIGEN; LAMININ; METALLOTHIONEIN; MINICHROMOSOME MAINTENANCE PROTEIN 2;

ADULT; AGED; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; DISEASE COURSE; FEMALE; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; METASTASIS POTENTIAL; MOUTH CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; DISEASE PROGRESSION; FEMALE; HUMANS; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MALE; METALLOTHIONEIN; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM INVASIVENESS; NUCLEAR PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 61449207405     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Leemans CR, Tiwari R, Nauta JJ, van der Waal I and Snow GB: Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer 73: 187-190, 1994.
2. Kainulainen T, Autio-Harmainen H, Oikarinen A, Salo S, Tryggvason K and Salo T: Altered distribution and synthesis of laminin 5 (kalinin) in oral lichen planus, epithelial dysplasias and squamous cell carcinomas. Br J Dermatol 136: 331-336, 1997.
3. Koshikawa N, Moriyama K, Takamura H, Mizushima H, Nagashima Y, Yanoma S and Miyazaki K: Overexpression of laminin g2 chain monomer in invading gastric carcinoma cells. Cancer Res 59: 5596-5601, 1999.
4. Pyke C, Romer J, Kallunki P, Lund LR, Ralfkiaer E, Dano K and Tryggvason K: The gamma 2 chain of kalinin/laminin 5 is preferentially expressed in invading malignant cells in human cancers. Am J Pathol 145: 782-791, 1994.
5. Maatta M, Soini Y, Paakko P, Salo S, Tryggvason K and Autio-Harmainen H: Expression of the laminin g2 chain in different histological types of lung carcinoma. A study by immunohistochemistry and in situ hybridization. J Pathol 188: 361-368, 1999.
6. Moriya Y, Niki T, Yamada T, Matsuno Y, Kondo H and Hirohashi S: Increased expression of laminin 5 and its prognostic significance in lung adenocarcinoma of small size. An immunohistochemical analysis of 102 cases. Cancer 91: 1129-1141, 2001.
7. Akashi T, Ito E, Eishi Y, Koike M, Nakamura K and Burgeson RE: Reduced expression of laminin a3 and a5 chains in non-small cell lung cancers. Jpn J Cancer Res 92: 293-301, 2001.
8. Stoltzfus P, Hogmo A, Lindholm J, Aspenblad U, Auer G and Munck-Wikland E: The gamma2 chain of laminin-5 as an indicator of increased risk for recurrence in T1 stage tongue cancer. Anticancer Res 24: 3109-3114, 2004.
9. Ono Y, Nakanishi Y, Ino Y, Niki T, Yamada T, Yoshimura K, Saikawa M, Nakajima T and Hirohashi S: Clinicopathologic significance of laminin-5 y2 chain expression in squamous cell carcinoma of the tongue. Cancer 85: 2315-2321, 1999.
10. Patarroyo M, Tryggvason K and Virtanen I: Laminin isoforms in tumor invasion, angiogenesis and metastasis. Cancer Biol 12: 197-207, 2002.
11. Tiger CF, Champliaud MF, Pedrosa-Domellof F, Thornell LE, Ekblom P and Gullberg D: Presence of laminin alpha 5 chain and lack of laminin alpha 1 chain during human muscle development and in muscular dystrophies. J Biol Chem 272: 28590-28595, 1997.
12. Tapiero H and Tew KD: Trace elements in human physiology and pathology: zinc and metallothioneins. Biomed Pharmacother 57: 399-411, 2003.
13. Cherian MG, Jayasurya A and Bay BH: Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat Res 533: 201-209, 2003.
14. Podhorska-Okolow M, Dziegiel P, Dolinska-Krajewska B, Dumanska M, Cegielski M, Jethon Z, Rossini K, Carraro U and Zabel M: Expression of metallothionein in renal tubules of rats exposed to acute and endurance exercise. Folia Histochem Cytobiol 44: 195-200, 2006.
15. Cardoso SV, Barbosa HM, Candellori IM, Loyola AM and Aguiar MC: Prognostic impact of metallothionein on oral squamous cell carcinoma. Virchows Arch 441: 174-178, 2002.
16. Hishikawa Y, Koji T, Dhar DK, Kinugasa S, Yamaguchi M and Nagasue N: Metallothionein expression correlates with metastatic and proliferative potential in squamous cell carcinoma of the oesophagus. Br J Cancer 81: 712-720, 1999.
17. Hiura T, Khalid H, Yamashita H, Tokunaga Y, Yasunaga A and Shibata S: Immunohistochemical analysis of metallothionein in astrocytic tumors in relation to tumor grade, proliferative potential, and survival. Cancer 83: 2361-2369, 1998.
18. Haerslev T, Jacobsen GK and Zedeler K: The prognostic significance of immunohistochemically detectable metallo-thionein in primary breast carcinomas. APMIS 103: 279-285, 1995.
19. Jasani B and Schmid KW: Significance of metallothionein over-expression in human tumours. Histopathology 31: 211-214, 1997.
20. Szelachowska J, Dziegiel P, Jelen-Krzeszewska J, Jelen M, Tarkowski R, Wlodarska I, Spytkowska B, Gisterek I, Matkowski R and Kornafel J: Prognostic significance of nuclear and cytoplasmic expression of metallothioneins as related to proliferative activity in squamous cell carcinomas of oral cavity. Histol Histopathol 23: 843-851, 2008.
21. Satoh M, Cherian MG, Imura N and Shimizu H: Modulation of resistance to anticancer drugs by inhibition of metallothionein synthesis. Cancer Res 54: 5255-5257, 1994.
22. Pastuszewski W, Dziegiel P, Krecicki T, Podhorska-Okolow M, Ciesielska U, Gorzynska E and Zabel M: Prognostic significance of metallothionein, p53 protein and Ki-67 antigen expression in laryngeal cancer. Anticancer Res 27: 335-342, 2007.
23. Dziegiel P, Forgacz J, Suder E, Surowiek P, Kornafel J and Zabel M: Prognostic significance of metallothionein expression in correlation with Ki-67 expression in adenocarcinomas of large intestine. Histol Histopathol 18: 401-407, 2003.
24. Dziegiel P, Salwa-Zurawska W, Zurawski J, Wojnar A and Zabel M: Prognostic significance of augmented metallothionein expression correlated with Ki-67 antigen expression in selected soft tissue sarcomas. Histol Histopathol 20: 83-89, 2005.
25. Krecicki T, Jelen M, Zalesska-Krecicka M, Rak J, Szkudlarek-Gruszczynska T and Jelen-Krzeszewska J: Epidermal growth factor receptor (EGFR), proliferating cell nuclear antigen (PCNA) and Ki-67 antigen in laryngeal epithelial lesions. Oral Oncol 35: 180-186, 1999.
26. Ofner D, Grothaus A and Riedmann B: MIB-I in colorectal carcinomas: its evaluation by three different methods reveals lack of prognostic significance. Anal Cell Path 12: 61-70,1996.
27. Tungekar MF, Gatter KC, Dunnill MS and Mason DY: Ki-67 immunostaining and survival in operable lung cancer. Histopathology 19: 545-550, 1991.
28. Bettendorf O and Herremann G: Prognostic relevance of Ki-67 antigen expression in 329 cases of oral squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec 64: 200-205, 2002.
29. Verheijen R, Kuijpers HJ, Schlingemann RO, Boehmer AL, van Driel R, Brakenhoff GJ and Ramaekers FC: Ki-67 detects a nuclear matrix-associated proliferation-related antigen. Intracellular localization during interphase: J Cell Sci 92: 123-130, 1989.
30. van Oijen MG, Medema RH, Slootweg PJ and Rijksen G: Positivity of the proliferation marker Ki-67 in noncycling cells. Am J Clin Pathol 110: 24-31, 1998.
31. Tye BK: Mem proteins in DNA replication. Annu Rev Biochem 68: 649-686, 1999.
32. Kearsey SE and Labib K: MCM proteins: evolution, properties and role in DNA replication. Biochim Biophys Acta 1398: 113-136, 1998.
33. Ritzi M and Knippers R: Initiation of genome replication: assembly and disassembly of replication-competent chromatin. Gene 245: 13-20, 2000.
34. Laskey RA and Madine MA: A rotary pumping model for helicase function of MCM proteins at a distance from replication forks. EMBO Rep 4: 26-30, 2003.
35. Romanowski P and Madine MA: Mechanisms restricting DNA replication to once per cell cycle: the role of Cdc 6 and ORC. Trends Cell Biol 7: 9-10, 1997.
36. Tye BK: Mem proteins in DNA replication. Annu Rev Biochem. 68: 649-686, 1999.
37. Stoeber K, Mills AD, Kubota Y, Krude T, Romanowski P, Marheineke K, Laskey RA and Williams GH: Cdc6 protein causes premature entry into S-phase in a mammalian cell-free system. EMBO J 17: 7219-7229, 1998.
38. Williams RS, Shohet RV and Stilman B: A human protein related to yeast Cdc6p. Proc Natl Acad Sci USA 94: 142-147, 1997.
39. Yan Z, DeGregori J, Shohet R, Leone G, Stillman B, Nevins JR and Williams RS: Cdc6 is regulated by E2F and is essential for DNA replication in mammalian cells. Proc Natl Acad Sci USA 95: 3603-3608, 1998.
40. Stoeber K, Tlsty TD, Happerfield L, Thomas GA, Romanov S, Bobrow I, Williams ED and Williams GH: DNA replication licensing and human cell proliferation. J Cell Sci 114: 2027-2041,2001.
41. Szelachowska J, Dziegiel P, Jelen-Krzeszewska J, Jelen M, Matkowski R, Pomiecko A, Spytkowska B, Jagas M, Gisterek I and Kornafel J: Mcm-2 protein expression predicts prognosis better than Ki-67 antigen in oral cavity squamocellular carcinoma. Anticancer Res 26: 2473-2478, 2006.
42. Sobin LH and Wittekind C (eds.): UICC TNM classification of malignant tumours. 5th edition. Berlin: Springer-Verlag, 1997.
43. Pindborg JJ, Reichart PA, Smith CJ and van der Waal I: Histological Typing of Cancer and Precancer of Oral Mucosa. Berlin: Springer-Verlag, 1997.
44. Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8: 138-140, 1987.
45. Dziegiel P and Zabel M: Role of immunohistochemical expression of Ki-67 in adenocarcinoma of large intestine. In: Handbook of Immunohistochemistry and In Situ Hybridization of Human Carcinomas. Hayat MA (ed.). Elsevier. Volume 4, pp. 127-134, 2006.
46. Lee SS, Yang SF, Ho YC, Tsai CH and Chang YC: The upregulation of metallothionein-1 expression in areca quid chewing-associated oral squamous cell carcinomas. Oral Oncol 44: 180-186, 2008.
47. Hishikawa Y, Kohno H, Ueda S, Kimoto T, Dhar DK, Kubota H, Tachibana M, Koji T and Nagasue N: Expression of metallothionein in colorectal cancers and synchronous liver metastases. Oncology 61: 162-167, 2001.
48. Weinlich G, Topar G, Eisendle K, Fritsch PO and Zeiger B: Comparison of metallothionein-overexpression with sentinel lymph node biopsy as prognostic factors in melanoma. J Eur Acad Dermatol Venereol 21: 669-677, 2007.
49. Endo T, Yoshikawa M, Ebara M, Kato K, Sunaga M, Fukuda H, Hayasaka A, Kondo F, Sugiura N and Saisho H: Immunohistochemical metallothionein expression in hepatocellular carcinoma: relation to tumor progression and chemoresistance to platinum agents. J Gastroenterol 39: 1196-1201, 2004.
50. Giuffre G, Barresi G, Sturniolo GC, Sarnelli R, D'Inca R and Tuccari G: Immunohistochemical expression of metallothionein in normal human colorectal mucosa, in adenomas and in adenocarcinomas and their associated metastases. Histopathology 29: 347-354, 1996.
51. Jayasurya A, Bay BH, Yap WM, Tan NG and Tan BK: Proliferative potential in nasopharyngeal carcinoma: correlations with metallothionein expression and tissue zinc levels. Carcinogenesis 21: 1809-1812, 2000.
52. Haga A, Nagase H, Kito H and Sato T: Effect of metallothioneins on transformation of gelatinase A from human fibroblast WI-38 cells. Cancer Letters 105: 175-180, 1996.
53. Kondo Y, Rusnak JM, Hoyt DG, Settineri CE, Pitt BR and Lazo JS: Enhanced apoptosis in metallothionein null cells. Mol Pharmacol 52: 195-201, 1997.
54. Abdel-Mageed AB and Agrawal KC: Activation of nuclear factor kappa B: potential role in metallothionein-mediated mitogenic response. Cancer Res 58: 2335-2338, 1998.
55. Nakshatri H and Goulet RJ Jr: NF-kappaB and breast cancer. Curr Probl Cancer 26: 282-309, 2002.